StockData
Embecta Corp. logo

Embecta Corp. (EMBC) stock

EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 15/3080% below fair value
$6.15−0.10 (-1.60%)

Close on Nov 17, 2026Market cap $348.46MP/E 4.2Yield 9.76%

Embecta r&d expenses

Research and development expenses are spending on new products and technology.

Embecta's R&D Expenses for the twelve months ending Jun 30, 2026 was $20.20M, down 61.5% year over year. For fiscal 2025 it was $37.30M, down 52.7% from the year before. The highest annual figure on record is $85.20M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$37.30M-52.7%
FY2024Sep 30, 2024$78.80M-7.5%
FY2023Sep 30, 2023$85.20M+27.4%
FY2022Sep 30, 2022$66.90M+5.7%
FY2021Sep 30, 2021$63.30M+3.1%
FY2020Sep 30, 2020$61.40M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$5.60M+27.3%
Q2 FY2026CQ1 2026Mar 31, 2026$5.40M-32.5%
Q1 FY2026CQ4 2025Dec 31, 2025$4.60M-77.3%
Q4 FY2025CQ3 2025Sep 30, 2025$4.60M-76.8%
Q3 FY2025CQ2 2025Jun 30, 2025$4.40M-78.4%
Q2 FY2025CQ1 2025Mar 31, 2025$8.00M-56.5%
Q1 FY2025CQ4 2024Dec 31, 2024$20.30M+0.5%
Q4 FY2024CQ3 2024Sep 30, 2024$19.80M-16.1%
Q3 FY2024CQ2 2024Jun 30, 2024$20.40M-9.7%
Q2 FY2024CQ1 2024Mar 31, 2024$18.40M-16.7%
Q1 FY2024CQ4 2023Dec 31, 2023$20.20M+19.5%
Q4 FY2023CQ3 2023Sep 30, 2023$23.60M+31.8%
Q3 FY2023CQ2 2023Jun 30, 2023$22.60M+58.0%
Q2 FY2023CQ1 2023Mar 31, 2023$22.10M+22.8%
Q1 FY2023CQ4 2022Dec 31, 2022$16.90M+1.2%
Q4 FY2022CQ3 2022Sep 30, 2022$17.90M-8.2%
Q3 FY2022CQ2 2022Jun 30, 2022$14.30M-8.9%
Q2 FY2022CQ1 2022Mar 31, 2022$18.00M+27.7%
Q1 FY2022CQ4 2021Dec 31, 2021$16.70M+19.3%
Q4 FY2021CQ3 2021Sep 30, 2021$19.50M–
Q3 FY2021CQ2 2021Jun 30, 2021$15.70M–
Q2 FY2021CQ1 2021Mar 31, 2021$14.10M–
Q1 FY2021CQ4 2020Dec 31, 2020$14.00M–

More Embecta figures

See a number that looks wrong?